PURPOSE: Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm. EXPERIMENTAL DESIGN: We studied 84 cases of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP)-treated DLBCL (47 GCB, 37 ABC) with GCET1, CD10, BCL6, MUM1, FOXP1, BCL2, MTA3, and cyclin D2 immunostains, and compared different combinations of the immunostaining results with the GEP classification. A perturbation analysis was also applied to eliminate the possible effects of interobserver or intraobserver variations. A separate set of 63 DLBCL cases treated with rituximab plus CHOP (37 GCB, 26 ABC) was used to validate the new algorithm. RESULTS: A new algorithm using GCET1, CD10, BCL6, MUM1, and FOXP1 was derived that closely approximated the GEP classification with 93% concordance. Perturbation analysis indicated that the algorithm was robust within the range of observer variance. The new algorithm predicted 3-year overall survival of the validation set [GCB (87%) versus ABC (44%); P < 0.001], simulating the predictive power of the GEP classification. For a group of seven primary mediastinal large B-cell lymphoma, the new algorithm is a better prognostic classifier (all "GCB") than the Hans' algorithm (two GCB, five non-GCB). CONCLUSION: Our new algorithm is significantly more accurate than the Hans' algorithm and will facilitate risk stratification of DLBCL patients and future DLBCL research using archival materials.
PURPOSE: Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm. EXPERIMENTAL DESIGN: We studied 84 cases of cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP)-treated DLBCL (47 GCB, 37 ABC) with GCET1, CD10, BCL6, MUM1, FOXP1, BCL2, MTA3, and cyclin D2 immunostains, and compared different combinations of the immunostaining results with the GEP classification. A perturbation analysis was also applied to eliminate the possible effects of interobserver or intraobserver variations. A separate set of 63 DLBCL cases treated with rituximab plus CHOP (37 GCB, 26 ABC) was used to validate the new algorithm. RESULTS: A new algorithm using GCET1, CD10, BCL6, MUM1, and FOXP1 was derived that closely approximated the GEP classification with 93% concordance. Perturbation analysis indicated that the algorithm was robust within the range of observer variance. The new algorithm predicted 3-year overall survival of the validation set [GCB (87%) versus ABC (44%); P < 0.001], simulating the predictive power of the GEP classification. For a group of seven primary mediastinal large B-cell lymphoma, the new algorithm is a better prognostic classifier (all "GCB") than the Hans' algorithm (two GCB, five non-GCB). CONCLUSION: Our new algorithm is significantly more accurate than the Hans' algorithm and will facilitate risk stratification of DLBCL patients and future DLBCL research using archival materials.
Authors: J K Frazer; D G Jackson; J P Gaillard; M Lutter; Y J Liu; J Banchereau; J D Capra; V Pascual Journal: Eur J Immunol Date: 2000-10 Impact factor: 5.532
Authors: Alison H Banham; Joseph M Connors; Philip J Brown; Jacqueline L Cordell; German Ott; Gayatri Sreenivasan; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne Journal: Clin Cancer Res Date: 2005-02-01 Impact factor: 12.531
Authors: A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell Journal: Cancer Res Date: 2001-12-15 Impact factor: 12.701
Authors: Naoyuki Fujita; David L Jaye; Masahiro Kajita; Cissy Geigerman; Carlos S Moreno; Paul A Wade Journal: Cell Date: 2003-04-18 Impact factor: 41.582
Authors: Yasodha Natkunam; Shuchun Zhao; David Y Mason; Jun Chen; Behnaz Taidi; Margaret Jones; Anne S Hammer; Stephen Hamilton Dutoit; Izidore S Lossos; Ronald Levy Journal: Blood Date: 2006-10-12 Impact factor: 22.113
Authors: Sharon L Barrans; Ian Carter; Roger G Owen; Faith E Davies; Russell D Patmore; Andrew P Haynes; Gareth J Morgan; Andrew S Jack Journal: Blood Date: 2002-02-15 Impact factor: 22.113
Authors: Philip J Brown; Sally L Ashe; Ellen Leich; Christof Burek; Sharon Barrans; James A Fenton; Andrew S Jack; Karen Pulford; Andreas Rosenwald; Alison H Banham Journal: Blood Date: 2007-12-12 Impact factor: 22.113
Authors: G Lenz; G Wright; S S Dave; W Xiao; J Powell; H Zhao; W Xu; B Tan; N Goldschmidt; J Iqbal; J Vose; M Bast; K Fu; D D Weisenburger; T C Greiner; J O Armitage; A Kyle; L May; R D Gascoyne; J M Connors; G Troen; H Holte; S Kvaloy; D Dierickx; G Verhoef; J Delabie; E B Smeland; P Jares; A Martinez; A Lopez-Guillermo; E Montserrat; E Campo; R M Braziel; T P Miller; L M Rimsza; J R Cook; B Pohlman; J Sweetenham; R R Tubbs; R I Fisher; E Hartmann; A Rosenwald; G Ott; H-K Muller-Hermelink; D Wrench; T A Lister; E S Jaffe; W H Wilson; W C Chan; L M Staudt Journal: N Engl J Med Date: 2008-11-27 Impact factor: 91.245
Authors: Javeed Iqbal; Paul N Meyer; Lynette M Smith; Nathalie A Johnson; Julie M Vose; Timothy C Greiner; Joseph M Connors; Louis M Staudt; Lisa Rimsza; Elaine Jaffe; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Wing C Chan Journal: Clin Cancer Res Date: 2011-09-20 Impact factor: 12.531
Authors: K K Wong; D M Gascoyne; P J Brown; E J Soilleux; C Snell; H Chen; L Lyne; C H Lawrie; R D Gascoyne; L M Pedersen; M B Møller; K Pulford; D Murphy; T M Green; A H Banham Journal: Leukemia Date: 2013-07-25 Impact factor: 11.528
Authors: Salah A Al-Humood; Aisha S Al-Qallaf; Salem H Alshemmari; Issam M Francis; Thamradeen A Junaid; Rajaa A Marouf; Fahd Al-Mulla Journal: J Histochem Cytochem Date: 2011-08-10 Impact factor: 2.479
Authors: Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young Journal: Clin Cancer Res Date: 2014-02-28 Impact factor: 12.531
Authors: Lianne Koens; Fenna H Heyning; Agota Szepesi; András Matolcsy; Pancras C W Hogendoorn; Patty M Jansen Journal: Virchows Arch Date: 2013-01-19 Impact factor: 4.064